Rock Springs Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Rock Springs Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-628,500	Closed	-$11M	–	157
2021 Q3	$11M	Hold	628,500	–	–	0.23%	104
2021 Q2	$6.1M	Buy	628,500 +7,700	+1%	+$72.5K	0.12%	132
2021 Q1	$6.67M	Buy	620,800 +2,300	+0.4%	+$28.4K	0.15%	126
2020 Q4	$9.1M	Sell	618,500 -152,418	-20%	-$2.2M	0.19%	115
2020 Q3	$11M	Buy	770,918 +8,300	+1%	+$82.8K	0.28%	97
2020 Q2	$6.17M	Buy	762,618 +12,618	+2%	+$78.1K	0.17%	123
2020 Q1	$3.03M	Buy	+750,000	New	+$2.83M	0.13%	116

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Rock Springs Capital Management's TRIL Position: Q4 2021 in Review

Rock Springs Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 628,500 shares — an estimated $11M sold.

Rock Springs Capital Management first reported a position in TRIL in Q1 2020 and held it in 7 quarters. The position peaked at $11M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Rock Springs Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Rock Springs Capital Management sold 628,500 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $11M.
Rock Springs Capital Management first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 7 quarters.
Rock Springs Capital Management's Trillium Therapeutics Inc. position peaked at $11M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.